XML 89 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Quarterly Information
 12 Months Ended
Dec. 31, 2012
Quarterly Information [Abstract]  
Quarterly information
Quarterly Information (Unaudited)
The following interim financial information presents the 2012 and 2011 results of operations on a quarterly basis:
2012
 
March 31
 
 
June 30
 
 
September 30
 
 
December 31
 
 
 
(Dollars in millions, except per share data)
 
Total revenues
$
2,830.4

 
$
2,841.3

 
$
2,779.6

 
$
2,837.8

(5)
Health plan services costs
2,343.7

 
2,358.5

 
2,281.4

 
2,332.8

 
Government contracts costs
162.3

 
153.4

 
151.8

 
137.5

 
(Loss) income from continuing operations before income taxes
(13.6
)
 
7.4

 
29.4

 
8.4

 
(Loss) income on discontinued operation, net of tax
(18.5
)
 
119.4

 
(2.5
)
 
(2.2
)
 
Net (loss) income
(26.6
)
(1)
124.6

(2)
18.0

(3)
6.0

(4), (5)
Basic (loss) earnings per share from continuing operations
$
(0.10
)
 
$
0.06

 
$
0.25

 
$
0.10

 
Diluted (loss) earnings per share from continuing operations (6)
$
(0.10
)
 
$
0.06

 
$
0.25

 
$
0.10

 
Basic (loss) earnings per share on discontinued operation
$
(0.22
)
 
$
1.44

 
$
(0.03
)
 
$
(0.03
)
 
Diluted (loss) earnings per share on discontinued operation (6)
$
(0.22
)
 
$
1.42

 
$
(0.03
)
 
$
(0.03
)
 
Basic (loss) earnings per share
$
(0.32
)
 
$
1.50

 
$
0.22

 
$
0.07

 
Diluted (loss) earnings per share (6)
$
(0.32
)
 
$
1.48

 
$
0.22

 
$
0.07

 
 
__________
(1)
Includes $25.0 million of adverse development related to prior periods recorded as part of health care costs, a $9.5 million expense related to our G&A cost reduction efforts and an unfavorable $0.7 million in pretax litigation reserve adjustment. Also includes a $6.5 million insurance reimbursement related to a prior legal settlement.
(2)
Includes $119.4 million gain on sale of discontinued operation related to the sale of our Medicare PDP business to CVS Caremark. Also, includes $7.9 million of adverse development related to prior years recorded as part of health care costs, and a $10.8 million expense related to our G&A cost reduction efforts.
(3)
Includes a $2.4 million unfavorable adjustment to the gain on sale of discontinued operation and a $7.2 million expense related to our G&A cost reduction efforts.
(4)
Includes a $2.2 million unfavorable adjustment to the gain on sale of discontinued operation, an $8.2 million expense related to our G&A cost reduction efforts, a $5.0 million expense related to the early termination of a medical management contract and $7.1 million of litigation-related expenses.
(5)
Includes $31.5 million of premium revenue as a result of Medicaid/Medi-Cal retroactive rate adjustment related to the third quarter of 2012 and prior periods.
(6)
The sum of the quarterly amounts may not equal the year-to-date amounts due to rounding.

2011
 
March 31
 
 
June 30
 
 
September 30
 
 
December 31
 
 
 
(Dollars in millions, except per share data)
 
Total revenues
$
3,363.2

 
$
2,652.3

 
$
2,692.0

 
$
2,708.0

 
Health plan services costs
2,117.3

 
2,123.3

 
2,149.3

 
2,149.9

 
Government contracts costs
822.2

 
130.8

 
127.9

 
157.0

 
(Loss) income from continuing operations before income taxes
(80.8
)
 
86.2

 
92.9

 
63.5

 
(Loss) income on discontinued operation, net of tax
(11.6
)
 
1.5

 
4.0

 
17.1

 
Net (loss) income
(108.2
)
(1)
58.3

(2)
61.8

(3)
60.2

(4)
Basic (loss) earnings per share from continuing operations
$
(1.04
)
 
$
0.63

 
$
0.66

 
$
0.52

 
Diluted (loss) earnings per share from continuing operations (5)
$
(1.04
)
 
$
0.62

 
$
0.65

 
$
0.51

 
Basic (loss) earnings per share on discontinued operation
$
(0.12
)
 
$
0.01

 
$
0.05

 
$
0.21

 
Diluted (loss) earnings per share on discontinued operation (5)
$
(0.12
)
 
$
0.01

 
$
0.05

 
$
0.20

 
Basic (loss) earnings per share
$
(1.16
)
 
$
0.64

 
$
0.71

 
$
0.73

 
Diluted (loss) earnings per share (5)
$
(1.16
)
 
$
0.63

 
$
0.70

 
$
0.71

 
 
__________
(1)
Includes a $177.2 million expense incurred as a result of the Louisiana Supreme Court’s judgment in the AmCareco litigation, an $11.0 million expense related to our cost management initiatives and a $34.9 million favorable adjustment to loss of sale of Northeast health plan subsidiaries.
(2)
Includes a $2.7 million expense related to our cost management initiatives, a $0.3 million benefit from litigation reserve adjustments and a $6.3 million favorable adjustment to loss on sale of Northeast health plan subsidiaries.
(3)
Includes a $4.7 million expense related to our cost management initiatives and a $0.2 million benefit from litigation reserve adjustments.
(4)
Includes a $9.7 million expense related to our cost management initiatives and a $6.3 million benefit from litigation reserve adjustments.
(5)
The sum of the quarterly amounts may not equal the year-to-date amounts due to rounding.